Graham gained his degree and PhD in Neuropharmacology from the University of Edinburgh Medical School. His more than 30 years of biopharmaceutical industry experience includes 10 years focusing on the discovery of novel compounds for the treatment of stroke and chronic pain (GSK, Pfizer, Servier) and 20 years in CNS clinical development in the biotech sector and with global CROs. Graham has worked on over 50 Phase I-IV clinical development programs including the planning and management of 13 Phase III programs with compounds that obtained NDA approval with the FDA. Most recently he held the position of VP, Clinical Development with the CNS focused biotech Travecta Therapeutics, and prior to that was VP, CNS Clinical Development with Syneos Health, providing scientific and strategic drug development expertise across a wide range of indications including dementia, movement disorders, stroke multiple sclerosis, mood disorders, acute & chronic pain and rare CNS diseases. Graham has been an invited speaker at several international conferences and has published 2 patents and over 25 scientific papers in major journals.
